Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3039790 | 0.98 | HRH3 (0.31) | HRH3 | |
| SCHEMBL3042472 | 0.98 | HRH3 (0.31) | HRH3 | |
| SCHEMBL8813629 | 0.98 | HRH3 (0.31) | HRH3 | |
| SCHEMBL3041225 | 0.93 | TDP1 (0.32) | HRH3TDP1 | |
| SCHEMBL104131 | 0.82 | — | — | |
| SCHEMBL3031784 | 0.80 | FFAR1 (0.30) | TDP1 | |
| SCHEMBL2281605 | 0.79 | — | — | |
| SCHEMBL7691462 | 0.76 | — | — | |
| SCHEMBL1766511 | 0.76 | MAOB (0.30) | — | |
| SCHEMBL7247772 | 0.76 | TDP1 (0.36) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026207-B2 | Peptides and compositions for inhibiting fungal growth | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | MATSUDA, AKIRA (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20090253636-A1 | Novel Antifungal Agent | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-2045256-A1 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216736-A2 | 2'-CYANOPYRIMIDINE NUCLEOSIDE COMPOUND | NUDT1, DPYD, SLC29A1 | HRH3 820/4885TDP1 775/4885 |
| US-20100056466-A1 | 2'-Cyanopyrimidine Nucleoside Compound | NUDT1, DPYD, SLC29A1 | HRH3 820/4885TDP1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.